Patients diagnosed with HCC were categorized into cohorts based on the levels of EZH2 expression, revealing significantly prolonged OS, disease-specific survival (DSS), and progression-free interval (PFI) in the low-EZH2 group (p < 0.001), with notably extended survival times (Fig. 3d–f). The gene discussed is EZH2; the disease is hepatocellular carcinoma.